A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Public ClinicalTrials.gov record NCT02588261. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Study identification
- NCT ID
- NCT02588261
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Enrollment
- 530 participants
Conditions and interventions
Conditions
Interventions
- Erlotinib Drug
- Gefitinib Drug
- naquotinib mesilate Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 10, 2016
- Primary completion
- Dec 20, 2017
- Completion
- Dec 20, 2017
- Last update posted
- Dec 9, 2024
2016 – 2017
United States locations
- U.S. sites
- 25
- U.S. states
- 14
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site US10029 | Beverly Hills | California | 90211 | — |
| Site US10025 | Fountain Valley | California | 90806 | — |
| Site US10036 | La Jolla | California | 92093 | — |
| Site US10051 | Loma Linda | California | 92350 | — |
| Site US10033 | Los Angeles | California | 90033 | — |
| Site US10031 | Oxnard | California | 93030 | — |
| Site US10052 | Redondo Beach | California | 90277 | — |
| Site US10003 | Santa Monica | California | 90404 | — |
| Site US10018 | Whittier | California | 90603 | — |
| Site US10047 | Glenwood Springs | Colorado | 81601 | — |
| Site US10013 | Aventura | Florida | 33180 | — |
| Site US10048 | St. Petersburg | Florida | 33705 | — |
| Site US10050 | Atlanta | Georgia | 30342 | — |
| Site US10042 | Baton Rouge | Louisiana | 70809 | — |
| Site US10037 | Scarborough | Maine | 04074 | — |
| Site US10034 | Boston | Massachusetts | 02111 | — |
| Site US10030 | Minneapolis | Minnesota | 55455 | — |
| Site US10027 | Rochester | Minnesota | 55905 | — |
| Site US10045 | Albuquerque | New Mexico | 87106 | — |
| Site US10012 | Mount Kisco | New York | 10549 | — |
| Site US10021 | Bethlehem | Pennsylvania | 18015 | — |
| Site US10009 | Nashville | Tennessee | 37203 | — |
| Site US10023 | Nashville | Tennessee | 37232 | — |
| Site US10011 | Lacey | Washington | 98503 | — |
| Site US10046 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 142 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02588261, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 9, 2024 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02588261 live on ClinicalTrials.gov.